The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation

The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts

(2010) Hichame Id Boufker et al.   BMC CANCER

The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo

(2010) Kate Vandyke et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts

(2010) Y-C Lee et al.   ONCOGENE

Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib

(2009) H. Schmid et al.   HAEMATOLOGICA

Growth deceleration in a girl treated with imatinib

(2009) Tomiko Kimoto et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Imatinib mesylate causes growth plate closure in vivo

(2009) K Vandyke et al.   LEUKEMIA

Rho-ROCK signaling differentially regulates chondrocyte spreading on fibronectin and bone sialoprotein

(2008) Kamal S. Gill et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty

(2008) Stefania Mariani et al.   LANCET

Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis

(2008) K Vandyke et al.   LEUKEMIA